Interní Med. 2010; 12(9): 424-426
Angiotensin-converting enzyme inhibitors and the fixed drug combination in practice
- Kardiovaskulární centrum, Kardiologické oddělení, Nemocnice Na Homolce, Praha
Angiotensin-converting enzyme inhibitors (ACEIs) have broad indication: ACEIs are widely used in the therapy of arterial hypertension,
cardiac dysfunction post myocardial infarction and in the management of chronic heart failure. Research showed other possibilities
of ACEIs use. Results of large clinical trials support importance of ACEIs in the cardiovascular event prevention in high risk subjects,
secondary prevention of ischemic stroke, and vascular complication in patients with diabetes mellitus. Current guidelines recommend
to start medical therapy of moderate to severe arterial hypertension with low dose of drug combination. ACEIs are reasoned choice for
drug combination thanks to their cardioprotective effect. ACEIs are now used for the medical therapy of arterial hypertension in the
combination with diuretics and calcium channel blockers.
prevention.
Keywords: angiotensin-converting enzyme inhibitors, fixed combination, diuretics, calcium channel blockers, cardiovascular disease,
Published: October 1, 2010 Show citation
References
- Souček M. Léčba hypertenze fixní kombinací - nové důkazy. Interní Med. 2009; 11(9): 369-375.
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
Go to original source... 
Go to PubMed... - The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
- PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
- 2007 Guidelines for the Management of Arterial Hypertension. J Hypertension 2007; 25: 1105-1187.
- Patel A and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients with type 2 diabetes mellitus (the ADVANCE trial). The Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
- Filipovský J. Studie ADVANCE - významný pokrok v předcházení kardiovaskulárním komplikacím u DM 2. typu. Kardio Rev 2007; 9(3): 191-192.
- Poulter NR, Peters R, Fletcher AE, et al. Role of blood pressure and other variables in the differential cardiovascular ebeny rates noted in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
- Jamerson KA, Weber MA, Bakris GL, et al. For the ACCOMPLISH Trial Investigators. Benazepril plus Amlodipin or Hydrochlorothiazide for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
- Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixedcombination perindopril/amlodipine. Curr Med Res Opin 2008; 24: 3543-3557. Go to original source... Go to PubMed...
- Vítovec J, Špinar J. Perindopril/indapamid - fixní kombinace. Remedia 2007; 17: 247-257.
- De Luca N, et al. On behalf of the REASON Project investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/ indapamide in hypertensive subjects. J Hypertens 2004; 22: 1623-1630. Go to original source... Go to PubMed...
- Pepine CJ, Handberg EM, Coper-DeHorf RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-8816. Go to original source... Go to PubMed...
- Widimský J. Kombinace inhibitoru ACE a blokátoru kalciových kanálů je optimální dvojkombinací léčby hypertenze. Vnitř Lék 2009; 55(2): 123-130. Go to PubMed...